Med Life Sa · BVB:M
Med Life Sa — 9M 2025 Earnings Presentation
17 slides from Med Life Sa's earnings presentation, Nov 14, 2025
Slide 1: 9mo 2025 Presentation
9mo 2025 Presentation 14 November 2025 www.medlife.ro www.medlife.ro
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
AGENDA 1 9mo 2025 Highlights • • Key messages Outlook 2 9mo 2025 • Profit and Loss • OPEX Evolution • Pro-forma Figures • Financial Position Financial • QoQ Evolution • Debt Position Results • Operational KPIs • Cash Flow 3 Q&A Session 3
Slide 4: 9mo 2025 Highlights
9mo 2025 Highlights • Key Messages • Outlook 1
Slide 5: Key messages
Key messages The Group achieved a consolidated pro-forma turnover of RON 2.36 billion in the first 9 months of the year, marking a 19.5% increase over the same period in 2024, driven by a robust demand for medical service, the gradual ramp-up of newly added capacities as well as the acquisitions fin
Slide 6: Outlook
Outlook • In the short and medium term, we expect the Group to maintain a stable trajectory, adopting a prudent approach while capitalizing on the available resources and opportunities to sustain strategic investments and adapt to the evolving macroeconomic environment. • We continue to closely moni
Slide 7: 9mo 2025 Financial Results
9mo 2025 Financial Results • Profit and Loss • Pro-forma Figures • QoQ Evolution • Operational KPIs • OPEX Evolution • Financial Position • Debt Position • Cash Flow 2
Slide 8: Statement of Profit and Loss
Statement of Profit and Loss 9M 2024 9M 2025 Pro-forma 9M 2025 Consolidated Pro-forma turnover % var. % var. IFRS IFRS adjusted Pro-forma reached RON 2.36bn, reflecting a Gross sales 1,978,668,707 2,361,915,728 19.4% 2,254,691 2,364,170,419 19.5% 19.5% YoY growth, driven by Net sales (less NHP) 1,97
Slide 9: Pro-forma Figures
Pro-forma Figures Pro-forma Revenues Pro-forma EBITDA 2,361,915,728 2,164,744,087 400,000,000 338,392,147 349,095,045 2,050,000,000 350,000,000 300,000,000 1,550,000,000 250,000,000 1,050,000,000 200,000,000 150,000,000 550,000,000 100,000,000 2,254,691 50,000,000 50,000,000 203,038 10,499,859 0 -45
Slide 10: QoQ Evolution
QoQ Evolution 120 EBITDA evolution (RON m vs % margin) 113.1 113.1 112.2 105.1 19.0% 98.1 95.1 96.7 100 17.2% 17.0% 72.2 74.7 75.8 80 71.2 15.2% 63.5 67.2 62.4 14.3% 14.5% 14.5% 14.2% 14.2% 14.1% 13.8% 15.0% 60 13.5% 48.6 13.5% 14.4% 12.5% 12.2% 13.0% 40 20 10.3% 11.0% 0 9.0% Q1 '22 Q2 '22 Q3 '22 Q4
Slide 11: Operational KPIs
Operational KPIs 9m 2024 9m 2025 % Total Business line Category % var. IFRS IFRS IFRS Sales Under IFRS, the Revenues recorded a 19.4% Revenue 741,702,586 884,149,472 19.2% 37.4% increase, with 15.5% driven by organic growth. Clinics Visits 3,181,076 3,615,877 13.7% Growth remained robust across the
Slide 12: OPEX Evolution
OPEX Evolution % OPEX % Sales 9m ‘24 9m ‘25 9m ‘24 9m ‘25 9m ‘24 9m ‘25 % var. var. var. IFRS IFRS IFRS IFRS IFRS IFRS Consumable materials and repair materials 358,380,674 465,271,058 29.8% 19.1% 20.7% 1.5 p.p 18.1% 19.7% 1.6 p.p Commodities 166,982,925 159,069,051 (4.7)% 8.9% 7.1% (1.8)p.p 8.4% 6.
Slide 13: Financial Position
Financial Position December 31, 2024 September 30, 2025 % var. IFRS IFRS Non-current assets 2,357,408,397 2,437,309,022 3.4% Current assets, excluding Cash and cash equivalents 546,097,224 520,195,381 (4.7)% Cash and cash equivalents 112,808,224 185,346,959 64.3% TOTAL ASSETS 3,016,313,845 3,142,851
Slide 14: Debt Position
Debt Position December 31, 2024 September 30, 2025 % var. IFRS IFRS Leasing liabilities Current portion – Leasing 108,288,263 106,325,941 (1.8)% As of 30 September 2025, the Net Long term portion - leasing 286,025,347 282,028,660 (1.4)% TOTAL 394,313,610 388,354,601 (1.5)% Debt to Pro-forma EBITDA r
Slide 15: Cash Flow
Cash Flow September 30, 2024 September 30, 2025 IFRS IFRS Net income before taxes 37,878,444 12,777,050 Adjustments for non-monetary items 255,606,909 328,375,311 Operating cash flow before working capital and other monetary changes 293,485,353 341,152,361 Cash used in working capital changes (19,74
Slide 16: Q&A session
Q&A session 3
Slide 17: Thank you!
MedLife Group 365, Calea Grivitei, Bucharest investors@medlife.ro Thank you!